All aducanumab articles
-
OpinionRegulators must follow their heads, not their hearts
The 2019 US approval of antibiotic Recarbrio seems not to have met the normally expected standards
-
Business
Second Alzheimer’s antibody approved in the US
Biogen–Eisai’s lecanemab can slow disease progression a little, but at significant cost and risk of side effects
-
Business
Alzheimer’s antibody engenders anticipation
Tantalising press-released data on Biogen and Eisai’s lecanemab prompt questions without firm answers
-
Opinion
Alzheimer’s, amyloid and abandoned antibodies
Biogen’s aducanumab is stumbling into obscurity. Where does that leave the amyloid hypothesis?
